Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

This study has been completed.
Sponsor:
Information provided by:
Takeda
ClinicalTrials.gov Identifier:
NCT00321984
First received: May 2, 2006
Last updated: April 25, 2011
Last verified: April 2011
  Purpose

The purpose of this study is to assess the efficacy and safety of Dexlansoprazole modified release (MR) (30 mg once daily [QD] or 60 mg QD) compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in subjects with symptomatic, nonerosive gastroesophageal reflux disease (GERD).


Condition Intervention Phase
Gastroesophageal Reflux Disease
Drug: Dexlansoprazole MR
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked.

  • Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked.


Secondary Outcome Measures:
  • Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Median [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.

  • Percentage of Days Without Nighttime Heartburn During Treatment as Assessed by Daily Electronic Diary-Mean [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.


Enrollment: 947
Study Start Date: June 2006
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dexlansoprazole MR 30 mg QD Drug: Dexlansoprazole MR
Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
Other Names:
  • TAK-390MR
  • Kapidex
  • Dexilant
Experimental: Dexlansoprazole MR 60 mg QD Drug: Dexlansoprazole MR
Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
Other Names:
  • TAK-390MR
  • Kapidex
  • Dexilant
Placebo Comparator: Placebo Drug: Placebo
Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.

Detailed Description:

This is a Phase 3, randomized, double-blind, multicenter, placebo-controlled, 3-arm study with a 4 week treatment period. This study will compare the efficacy of Dexlansoprazole MR (30 mg QD and 60 mg QD) with that of placebo when administered orally as a single daily dose in the morning, before breakfast. The study is designed to evaluate symptom relief in subjects with symptomatic nonerosive GERD. Approximately 900 subjects will be enrolled at approximately 200 United States (US) and potentially ex-US sites. The study consists of two periods: a screening period, which will last a minimum of 7 days and a maximum of 21 days, and a treatment period, which will last 4 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects identifying their main symptom as a burning feeling in the mid epigastric area and/or chest area (ie, heartburn).
  • Subject has a history of episodes of heartburn for 6 months or longer prior to Screening.
  • Subject must have a history of episodes of heartburn for 4 or more days during the 7 days prior to Day -1.

Exclusion Criteria:

  • Endoscopic Barrett's esophagus and/or definite dysplastic changes. History of dilatation of esophageal strictures.
  • Subjects with erosive esophagitis (EE) as shown by endoscopy.
  • Evidence of uncontrolled systemic disease. Co-existing diseases affecting the esophagus. Current or history of Zollinger-Ellison syndrome.
  • Subject has abnormal laboratory values.
  • Subjects with active gastric or duodenal ulcers within 4 weeks of the first dose.
  • Subject known to have acquired immunodeficiency syndrome (AIDS).
  • Known hypersensitivity to any proton pump inhibitor (PPI), any component of Dexlansoprazole MR, or antacid.
  • Use of prescription or non-prescription PPIs, histamine (H2) receptor antagonists, or sucralfate.
  • Chronic (>12 doses per month) use of nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors.
  • Use of antacids (except for study-supplied Gelusil® ).
  • Use of drugs with significant anticholinergic effects.
  • Subjects who cannot discontinue the use of misoprostol or prokinetics
  • Need for continuous anticoagulant therapy.
  • Females who are pregnant or lactating.
  • History of gastrointestinal surgery except for simple oversew of ulcer.
  • History of cancer within 3 years prior to screening.
  • Subject has participated in a previous Dexlansoprazole study.
  • Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00321984

  Hide Study Locations
Locations
United States, Alabama
Alabaster, Alabama, United States
Birmingham, Alabama, United States
Hueytown, Alabama, United States
Huntsville, Alabama, United States
Northport, Alabama, United States
Tallassee, Alabama, United States
United States, Arizona
Chandler, Arizona, United States
North Little Rock, Arizona, United States
Sun City, Arizona, United States
Tempe, Arizona, United States
Tucson, Arizona, United States
United States, California
Anaheim, California, United States
Azusa, California, United States
Carmichael, California, United States
Chula Vista, California, United States
Clearwater, California, United States
Cypress, California, United States
Fountain Valley, California, United States
Fullerton, California, United States
Garden Grove, California, United States
Irvine, California, United States
Lancaster, California, United States
Mission Hills, California, United States
Oakland, California, United States
Orange, California, United States
Palm Springs, California, United States
Pasadena, California, United States
Redwood City, California, United States
San Diego, California, United States
San Francisco, California, United States
San Luis Obispo, California, United States
Vista, California, United States
Westlake Village, California, United States
United States, Colorado
Boulder, Colorado, United States
Colorado Springs, Colorado, United States
Littleton, Colorado, United States
Lone Tree, Colorado, United States
Wheat Ridge, Colorado, United States
United States, Connecticut
Bristol, Connecticut, United States
Waterbury, Connecticut, United States
United States, Florida
Boynton Beach, Florida, United States
Clearwater, Florida, United States
Holly Hill, Florida, United States
Jupitor, Florida, United States
Kissimmee, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
New Smyma Beach, Florida, United States
Ocala, Florida, United States
Pembroke Pines, Florida, United States
Saint Petersburg, Florida, United States
West Palm Beach, Florida, United States
Zephyrhills, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Conyers, Georgia, United States
Dunwoody, Georgia, United States
Stockbridge, Georgia, United States
United States, Hawaii
Honolulu, Hawaii, United States
United States, Idaho
Boise, Idaho, United States
United States, Illinois
Moline, Illinois, United States
Oak Forrest, Illinois, United States
Rockford, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Iowa
Clive, Iowa, United States
Dubuque, Iowa, United States
United States, Kansas
Overland, Kansas, United States
Wichita, Kansas, United States
United States, Kentucky
Lexington, Kentucky, United States
Louisville, Kentucky, United States
United States, Louisiana
Baton Rouge, Louisiana, United States
Metairie, Louisiana, United States
United States, Maryland
Baltimore, Maryland, United States
Chevy Chase, Maryland, United States
Hollywood, Maryland, United States
Lutherville, Maryland, United States
Prince Frederick, Maryland, United States
United States, Michigan
Troy, Michigan, United States
United States, Minnesota
Chaska, Minnesota, United States
United States, Mississippi
Jackson, Mississippi, United States
Olive Branch, Mississippi, United States
United States, Missouri
Jefferson City, Missouri, United States
Mexico, Missouri, United States
Washington, Missouri, United States
United States, Montana
Butte, Montana, United States
United States, Nevada
Las Vegas, Nevada, United States
Pahrump, Nevada, United States
United States, New Jersey
Egg Harbor Town, New Jersey, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Binghamton, New York, United States
Great Neck, New York, United States
Rochester, New York, United States
United States, North Carolina
Charlotte, North Carolina, United States
Greensboro, North Carolina, United States
Harrisburg, North Carolina, United States
High Point, North Carolina, United States
Raleigh, North Carolina, United States
Statesville, North Carolina, United States
United States, North Dakota
Bismark, North Dakota, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Kettering, Ohio, United States
Lyndhurst, Ohio, United States
Mogadore, Ohio, United States
Sylvania, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
Medford, Oregon, United States
Portland, Oregon, United States
United States, Pennsylvania
Duncansville, Pennsylvania, United States
Harleysville, Pennsylvania, United States
Lansdale, Pennsylvania, United States
Levittown, Pennsylvania, United States
United States, South Carolina
Anderson, South Carolina, United States
Charleston, South Carolina, United States
Mount Pleasant, South Carolina, United States
Varnville, South Carolina, United States
United States, South Dakota
Sioux Falls, South Dakota, United States
United States, Tennessee
Bristol, Tennessee, United States
Chattanooga, Tennessee, United States
Germantown, Tennessee, United States
Hermitage, Tennessee, United States
Jackson, Tennessee, United States
Johnson City, Tennessee, United States
Kingsport, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Amarillo, Texas, United States
Austin, Texas, United States
Beaumont, Texas, United States
Bellaire, Texas, United States
Bryan, Texas, United States
Carollton, Texas, United States
Conroe, Texas, United States
Corsicana, Texas, United States
Dallas, Texas, United States
El Paso, Texas, United States
Fort Worth, Texas, United States
Houston, Texas, United States
Lake Jackson, Texas, United States
San Antonio, Texas, United States
United States, Utah
Midvale, Utah, United States
Ogden, Utah, United States
Salt Lake City, Utah, United States
United States, Virginia
Charlottesville, Virginia, United States
Chesapeake, Virginia, United States
Norfold, Virginia, United States
Richmond, Virginia, United States
United States, Washington
Lakewood, Washington, United States
Spokane, Washington, United States
Tacoma, Washington, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Monroe, Wisconsin, United States
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Takeda
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Sr. VP Clinical Sciences, Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier: NCT00321984     History of Changes
Other Study ID Numbers: T-GD05-137, 2006-000420-13, U1111-1114-1935
Study First Received: May 2, 2006
Results First Received: February 26, 2009
Last Updated: April 25, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Gastroesophageal Reflux Disease(GERD)
Heartburn

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Dexlansoprazole
Lansoprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on October 16, 2014